Literature DB >> 12954335

Development and characterization of nonpeptidic small molecule inhibitors of the XIAP/caspase-3 interaction.

Tom Y H Wu1, Klaus W Wagner, Badry Bursulaya, Peter G Schultz, Quinn L Deveraux.   

Abstract

Elevated expression of inhibitor of apoptosis protein (IAP) family members in various types of cancers is thought to provide a survival advantage to these cells. Thus, antiapoptotic functions of IAPs, and their potential as novel anticancer targets have attracted considerable interest. Among the IAPs, the X chromosome-linked inhibitor of apoptosis protein (XIAP) is regarded as the most potent suppressor of mammalian apoptosis through direct binding and inhibition of caspases. A high-throughput biochemical screen of a combinatorial chemical library led to the discovery of a novel nonpeptidic small molecule that has the ability to disrupt the XIAP/caspase-3 interaction. The activity of this nonpeptidic small molecule inhibitor of the XIAP/caspase-3 interaction has been characterized both in vitro and in cells. Molecules of this type can be used to conditionally inhibit the cellular function of XIAP and may provide insights into the development of therapeutic agents that act by modulating apoptotic pathways.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12954335     DOI: 10.1016/s1074-5521(03)00157-1

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  32 in total

Review 1.  Role of Bcl-2 family proteins and caspases in the regulation of apoptosis.

Authors:  Mohammad Shamsul Ola; Mohd Nawaz; Haseeb Ahsan
Journal:  Mol Cell Biochem       Date:  2011-01-06       Impact factor: 3.396

Review 2.  Caspases: pharmacological manipulation of cell death.

Authors:  Inna N Lavrik; Alexander Golks; Peter H Krammer
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

Review 3.  Induction of apoptosis in lymphoid and myeloid leukemia.

Authors:  Aaron D Schimmer
Journal:  Curr Oncol Rep       Date:  2006-11       Impact factor: 5.075

4.  An unconventional IAP-binding motif revealed by target-assisted iterative screening (TAIS) of the BIR3-cIAP1 domain.

Authors:  Alexei Kurakin; Dale E Bredesen
Journal:  J Mol Recognit       Date:  2007 Jan-Feb       Impact factor: 2.137

5.  Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP.

Authors:  Haiying Sun; Zaneta Nikolovska-Coleska; Jianfeng Lu; Jennifer L Meagher; Chao-Yie Yang; Su Qiu; York Tomita; Yumi Ueda; Sheng Jiang; Krzysztof Krajewski; Peter P Roller; Jeanne A Stuckey; Shaomeng Wang
Journal:  J Am Chem Soc       Date:  2007-11-14       Impact factor: 15.419

Review 6.  Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function.

Authors:  Casey W Wright; Colin S Duckett
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

7.  Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis.

Authors:  Sean L Petersen; Lai Wang; Asligul Yalcin-Chin; Lin Li; Michael Peyton; John Minna; Patrick Harran; Xiaodong Wang
Journal:  Cancer Cell       Date:  2007-11       Impact factor: 31.743

8.  Fragment-based design of small molecule X-linked inhibitor of apoptosis protein inhibitors.

Authors:  Jui-Wen Huang; Ziming Zhang; Bainan Wu; Jason F Cellitti; Xiyun Zhang; Russell Dahl; Chung-Wai Shiau; Kate Welsh; Aras Emdadi; John L Stebbins; John C Reed; Maurizio Pellecchia
Journal:  J Med Chem       Date:  2008-11-27       Impact factor: 7.446

Review 9.  Harnessing the apoptotic programs in cancer stem-like cells.

Authors:  Ying-Hua Wang; David T Scadden
Journal:  EMBO Rep       Date:  2015-08-07       Impact factor: 8.807

10.  E9-Im9 colicin DNase-immunity protein biomolecular association in water: a multiple-copy and accelerated molecular dynamics simulation study.

Authors:  Riccardo Baron; Sergio E Wong; Cesar A F de Oliveira; J Andrew McCammon
Journal:  J Phys Chem B       Date:  2008-12-25       Impact factor: 2.991

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.